Shire Adds to Rare Disease Portfolio with Acquisition of Lumena Pharmaceuticals, Bringing Late Stage Compounds for Rare GI/Hepatic Conditions

[PR Newswire] – Adds to Shire’s rare diseases portfolio and leverages this expertise, and is a perfect combination with Shire’s already strong Gastrointestinal (GI) presence Very attractive opportunity to develop treatments for significant unmet need in more

View todays social media effects on SHPG

View the latest stocks trending across Twitter. Click to view dashboard

See who Shire is hiring next, click here to view